Patent · US Active

Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production

US8501709B2 · kind B2 · utility

3Cited by

1References

16Claims

0Family size

Assignee

K.U. Leuven Research & Development · BE

Inventors

Piet Herdewijn · Wezemaal, BE
Christophe Pannecouque · Heverlee, BE
Tongfei Wu · Leuven, BE
Erik De Clercq · Lovenjoel, BE

Key dates

Filing date	Nov 8, 2011
Grant date	Aug 6, 2013
Priority date	—
Expiry date	Nov 8, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07H19/16
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention is directed to phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base, as well as pharmaceutical compositions thereof. These compounds, which can be described by general formula (II), are useful for the treatment of retroviral infection, e.g., HIV (Human Immunodeficiency Virus) infection in a mammal. The invention also features synthetic intermediates for the preparation of phosphonate nucleosides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.